- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00003917
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.
연구 개요
상세 설명
OBJECTIVES: I. Compare the response rate, response duration, time to response, time to progression, and survival of patients with relapsed limited or extensive stage small cell lung cancer treated with oral vs intravenous topotecan. II. Compare the qualitative and quantitative toxicities of these treatment regimens in this patient population. III. Compare the quality of life in these patients.
OUTLINE: This is randomized, multicenter study. Patients are stratified according to gender, liver metastases (yes vs no), and duration of response to prior chemotherapy (6 months or less vs greater than 6 months). Patients are randomized to one of two treatment arms. Arm I: Patients receive topotecan IV over 30 minutes on days 1-5. Arm II: Patients receive topotecan orally on days 1-5. Treatment repeats every 3 weeks in the absence of unacceptable toxicity. Patients experiencing complete or partial response continue until progression or for at least 2 courses past maximal response. Patients with stable disease should receive at least 4 courses. Quality of life is assessed Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this study.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, 미국, 85012
- Veterans Affairs Medical Center - Phoenix (Hayden)
-
-
California
-
Bakersfield, California, 미국, 93309
- Comprehensive Blood and Cancer Center
-
Fountain Valley, California, 미국, 92708
- Pacific Coast Hematology/Oncology Medical Group
-
La Jolla, California, 미국, 92037
- Scripps Clinic
-
Los Angeles, California, 미국, 90073
- Veterans Affairs Medical Center - West Los Angeles
-
Poway, California, 미국, 92064
- Southwest Cancer Care
-
Sacramento, California, 미국, 95817
- University of California Davis Cancer Center
-
San Diego, California, 미국, 92120
- Kaiser Permanente-Southern California Permanente Medical Group
-
San Diego, California, 미국, 92121
- Sidney Kimmel Cancer Center
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80909
- Oncology Clinic, P.C.
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- Shands Cancer Center
-
Jacksonville, Florida, 미국, 32207
- Baptist Regional Cancer Institute - Jacksonville
-
Miami, Florida, 미국, 33176
- Oncology-Hematology Group of South Florida
-
Pensacola, Florida, 미국, 32522
- Baptist Hospital- Pensacola
-
Tampa, Florida, 미국, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Augusta, Georgia, 미국, 30912-3620
- Medical College of Georgia Hospital and Clinics
-
-
Illinois
-
Evanston, Illinois, 미국, 60201
- Evanston Northwestern Health Care
-
Hines, Illinois, 미국, 60141
- Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46219
- Oncology and Hematology Associates, Inc.
-
-
Louisiana
-
Lafayette, Louisiana, 미국, 70506
- Louisiana Oncology Associates
-
New Orleans, Louisiana, 미국, 70121
- Alton Ochsner Medical Foundation Hospital
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- Henry Ford Hospital
-
Pontiac, Michigan, 미국, 48341-2985
- St. Joseph Mercy Hospital
-
-
Minnesota
-
Saint Louis Park, Minnesota, 미국, 55416
- CCOP - Metro-Minnesota
-
-
Missouri
-
Saint Louis, Missouri, 미국, 63141
- St. John's Mercy Medical Center
-
-
New Jersey
-
Camden, New Jersey, 미국, 08103
- Cooper Cancer Institute
-
Livingston, New Jersey, 미국, 07039
- St. Barnabas Medical Center
-
Voorhees, New Jersey, 미국, 08043
- Cooper Hospital/University Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, 미국, 87505
- Santa Fe Hematology/Oncology
-
-
New York
-
Rochester, New York, 미국, 14621
- Rochester General Hospital
-
Syracuse, New York, 미국, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem, North Carolina, 미국, 27103
- Salem Research
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106-5065
- Ireland Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- Penn State Geisinger Cancer Center
-
Lemoyne, Pennsylvania, 미국, 17043-1440
- Central Pennsylvania Hematology & Medical Oncology Associates, PC
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh Cancer Institute
-
Reading, Pennsylvania, 미국, 19612-6052
- Reading Hospital and Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02912
- Brown University Oncology Group
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- Cancer Centers of the Carolinas
-
Spartanburg, South Carolina, 미국, 29303
- Spartanburg Regional Healthcare System
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37901
- Baptist Regional Cancer Center - Knoxville
-
Nashville, Tennessee, 미국, 37203
- Sarah Cannon-Minnie Pearl Cancer Center
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- Texas Cancer Care
-
Galveston, Texas, 미국, 77555-0209
- University of Texas Medical Branch
-
Houston, Texas, 미국, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Lubbock, Texas, 미국, 79410
- Joe Arrington Cancer Center
-
Temple, Texas, 미국, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- Office of Michael E. Lee
-
Richmond, Virginia, 미국, 23226
- Hematology & Oncology Associates of Virginia
-
Roanoke, Virginia, 미국, 24014
- Oncology and Hematology Associates of Southwest Virginia, Inc.
-
-
Wisconsin
-
Waukesha, Wisconsin, 미국, 53188
- Waukesha Memorial Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited or extensive stage small cell lung cancer (SCLC) Disease recurring at least 90 days following completion of first line chemotherapy Partial or complete response to first line therapy Must have at least one bidimensionally measurable non CNS lesion May be within a prior radiation port if at least 6 weeks since prior radiotherapy and progressing Brain and/or leptomeningeal metastases allowed if asymptomatic and not requiring corticosteroids
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 2 months Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL (after transfusion, if needed) Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active uncontrolled infection No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I low grade prostate cancer No other severe medical conditions that would preclude study or cause exposure to extreme risk or decreased life expectancy No uncontrolled emesis No active peptic ulcer, diabetes mellitus, chronic gastritis, significant ascites, or other gastrointestinal (GI) conditions (e.g., removal of a portion of the stomach or recent GI obstruction) that would alter absorption or GI motility No history of allergic reactions to compounds chemically related to topotecan Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for 3 months prior to, during, and at least 4 weeks after the study
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No concurrent immunotherapy for SCLC Chemotherapy: See Disease Characteristics No prior topotecan Only one prior chemotherapy regimen allowed No other concurrent chemotherapy for SCLC Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 24 hours since prior radiotherapy No concurrent radiotherapy for SCLC Surgery: At least 4 weeks since prior surgery Other: At least 30 days or five half lives since other prior investigational drugs No prior drugs (e.g., cisapride) that would alter absorption or GI motility No other concurrent investigational therapy for SCLC
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 단일 그룹 할당
공동 작업자 및 조사자
수사관
- 연구 의자: Nathan Levitan, MD, Case Comprehensive Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SKF1598
- CWRU-SKF-1598
- SB-104864-A/396
- NCI-G99-1524
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
폐암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
토포테칸 염산염에 대한 임상 시험
-
Haihe Biopharma Co., Ltd.Shanghai Institute of Materia Medica, Chinese Academy of Sciences완전한
-
Torrent Pharmaceuticals Limited완전한
-
Bing He모집하지 않고 적극적으로
-
University Hospital Southampton NHS Foundation...University of Southampton빼는
-
Torrent Pharmaceuticals Limited완전한
-
Aziende Chimiche Riunite Angelini Francesco S.p.AZak-Pharma Dienstleistung Ges.m.b.H.완전한
-
Xian-Janssen Pharmaceutical Ltd.완전한